Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Post-Market Study Or Marketing Plug? Government Attorneys Are On Watch

This article was originally published in The Gray Sheet

Executive Summary

Government investigators say they are increasingly on watch for post-market device studies designed to make a sale or explore an off-label use, rather than for bona fide clinical research.

You may also be interested in...

News In Brief

St. Jude Medical inks DOJ settlement

Boston Scientific settles kickback charges

Firm will pay $22 million to settle civil charges that its Guidant subsidiary used four post-market studies as vehicles to pay kickbacks to physicians for implanting its defibrillators and pacemakers. Guidant, which was acquired by Boston Scientific in 2006, allegedly paid participating physicians $1,000-$1,500 per study in 2003 and 2004. The settlement, announced Dec. 23, closes a Department of Justice investigation initiated in 2005 into Guidant product feedback surveys (1"The Gray Sheet" Oct. 31, 2005). Boston Scientific admits no wrongdoing under the settlement, which also includes a corporate integrity agreement with the HHS Office of Inspector General. The agreement requires the company's cardiac rhythm management business to publish its payments to doctors on the Internet, as well as make "enhancements to certain compliance procedures related to financial arrangements with health care providers," according to Boston Scientific. Although device and drug makers "can use post-market studies legitimately to obtain information about how their products work in the field, they cannot use those studies, and the honoraria associated with them, to induce physicians to use their products," said U.S. Attorney Carmen M. Ortiz. Boston Scientific recently settled a separate Justice Department investigation, also initiated in 2005, into possible lapses in Guidant's product safety reporting to FDA (2"The Gray Sheet" Nov. 9, 2009)

QUOTED. 20 February 2020. Steven Raman.

Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts